Monday, May 12, 2025
spot_img

ASM share buyback update May 5 – 9, 2025

Almere, The Netherlands
May 12, 2025, 5:45 p.m. CET

ASM International N.V. (Euronext Amsterdam: ASM) reports the following transactions, conducted under ASM’s current share buyback program.

Date Repurchased shares Average price Repurchased value
May 5, 2025 3,824 € 440.73 € 1,685,336
May 6, 2025 4,694 € 431.58 € 2,025,845
May 7, 2025 4,502 € 435.59 € 1,961,005
May 8, 2025 1,758 € 453.75 € 797,695
May 9, 2025 2,802 € 452.48 € 1,267,854
Total 17,580 € 440.14 € 7,737,735

These repurchases were made as part of the €150 million share buyback program which started on April 30, 2025. Of the total program, 7.4% has been repurchased. For further details including individual transaction information please visit: www.asm.com/investors/dividends-share-buybacks.

About ASM International

ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia. ASM International’s common stock trades on the Euronext Amsterdam Stock Exchange (symbol: ASM). For more information, visit ASM’s website at www.asm.com.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Contact

Investor and media relations

Victor Bareño
T: +31 88 100 8500
E: [email protected]

 

Investor relations

Valentina Fantigrossi
T: +31 88 100 8502
E: [email protected]

Powered by SlickText.com

Hot this week

Team, Inc. Reports First Quarter 2025 Results

SUGAR LAND, Texas, May 12, 2025 (GLOBE...

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) --...

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

First of several clinical updates through mid-2026 accepted for...

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

KEY HIGHLIGHTS First patient expected to start therapy...

Topics

spot_img

Related Articles

Popular Categories

spot_img